Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome
Authors
Keywords
-
Journal
CNS SPECTRUMS
Volume 21, Issue 05, Pages 355-359
Publisher
Cambridge University Press (CUP)
Online
2016-09-30
DOI
10.1017/s1092852916000602
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors
- (2016) Stephen M. Stahl CNS SPECTRUMS
- Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management
- (2016) Anna Chang et al. DRUGS
- The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson’s disease
- (2016) Stefan Hermanowicz et al. Expert Review of Neurotherapeutics
- Quetiapine for Psychosis in Parkinson Disease and Neurodegenerative Parkinsonian Disorders
- (2016) Philippe Desmarais et al. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
- The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson’s disease
- (2016) Stefan Hermanowicz et al. Expert Review of Neurotherapeutics
- Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations
- (2016) Ahmad A. Khundakar et al. Acta Neuropathologica Communications
- Serotonin in Parkinson's disease
- (2015) Marios Politis et al. BEHAVIOURAL BRAIN RESEARCH
- Dorsal-to-Ventral Shift in Midbrain Dopaminergic Projections and Increased Thalamic/Raphe Serotonergic Function in Early Parkinson Disease
- (2015) J. Joutsa et al. JOURNAL OF NUCLEAR MEDICINE
- Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase
- (2015) Javier Pagonabarraga et al. MOVEMENT DISORDERS
- New insight into the therapeutic role of the serotonergic system in Parkinson's disease
- (2015) Yukihiro Ohno et al. PROGRESS IN NEUROBIOLOGY
- Comprehensive treatment of dementia with Lewy bodies
- (2015) Brendon P Boot Alzheimers Research & Therapy
- Treatment of Psychosis and Dementia in Parkinson’s Disease
- (2014) Jennifer G. Goldman et al. Current Treatment Options in Neurology
- Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations
- (2014) Sandra A. Jacobson et al. PARKINSONISM & RELATED DISORDERS
- Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
- (2013) Jeffrey H. Kordower et al. BRAIN
- Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management
- (2013) Clive Ballard et al. DRUGS & AGING
- Pimavanserin for the treatment of Parkinson's disease psychosis
- (2013) Joseph H Friedman EXPERT OPINION ON PHARMACOTHERAPY
- Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations
- (2013) M. Kometer et al. JOURNAL OF NEUROSCIENCE
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Dopamine overdose hypothesis: Evidence and clinical implications
- (2013) David E. Vaillancourt et al. MOVEMENT DISORDERS
- The serotonergic system in motor and non-motor manifestations of Parkinson’s disease
- (2013) Philippe Huot et al. EXPERIMENTAL BRAIN RESEARCH
- Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function
- (2012) Alex A. MacDonald et al. MOVEMENT DISORDERS
- Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease
- (2012) Bernard Ravina et al. MOVEMENT DISORDERS
- An update expert opinion on management and research strategies in Parkinson's disease psychosis
- (2011) Jennifer G Goldman et al. EXPERT OPINION ON PHARMACOTHERAPY
- Increased 5-HT2Areceptors in the temporal cortex of parkinsonian patients with visual hallucinations
- (2010) Philippe Huot et al. MOVEMENT DISORDERS
- Pathophysiology and Treatment of Psychosis in Parkinson’s Disease
- (2009) Laura B Zahodne et al. DRUGS & AGING
- Serotonin and Parkinson's disease: On movement, mood, and madness
- (2009) Susan H. Fox et al. MOVEMENT DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now